{"id":"topical-corticosteroid-tcs","safety":{"commonSideEffects":[{"rate":"null","effect":"Skin atrophy"},{"rate":"null","effect":"Hypopigmentation"},{"rate":"null","effect":"Allergic contact dermatitis"}]},"_chembl":{"chemblId":"CHEMBL2425825","moleculeType":"Small molecule","molecularWeight":"279.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"They do this by inhibiting the production of pro-inflammatory cytokines and other mediators of inflammation, thereby reducing the severity of symptoms associated with conditions such as eczema, psoriasis, and dermatitis.","oneSentence":"Topical corticosteroids reduce inflammation by suppressing the immune system's response to perceived threats.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:24.322Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Eczema"},{"name":"Psoriasis"},{"name":"Dermatitis"}]},"trialDetails":[{"nctId":"NCT06311682","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"LEO Pharma","startDate":"2024-06-10","conditions":"Atopic Dermatitis","enrollment":195},{"nctId":"NCT06701331","phase":"PHASE3","title":"Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-12-22","conditions":"Atopic Dermatitis","enrollment":99},{"nctId":"NCT05559359","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-10-18","conditions":"Atopic Dermatitis, Eczema","enrollment":367},{"nctId":"NCT05704738","phase":"PHASE3","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":532},{"nctId":"NCT03568318","phase":"PHASE3","title":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-09","conditions":"Atopic Dermatitis","enrollment":1533},{"nctId":"NCT06627335","phase":"","title":"An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-03-27","conditions":"Pregnancy Related, Atopic Dermatitis","enrollment":5621},{"nctId":"NCT05724199","phase":"PHASE3","title":"A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-02-21","conditions":"Atopic Dermatitis","enrollment":746},{"nctId":"NCT06280716","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Atopic Dermatitis","enrollment":301},{"nctId":"NCT04202679","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-01-16","conditions":"Neurodermatitis","enrollment":160},{"nctId":"NCT04183335","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-12","conditions":"Neurodermatitis","enrollment":151},{"nctId":"NCT06554847","phase":"PHASE3","title":"Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-09-23","conditions":"Dermatitis, Atopic, Eczema, Atopic","enrollment":400},{"nctId":"NCT05607901","phase":"PHASE2","title":"A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-28","conditions":"Dermatologic Disease","enrollment":100},{"nctId":"NCT03160885","phase":"PHASE3","title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-06-12","conditions":"Atopic Dermatitis","enrollment":794},{"nctId":"NCT04587453","phase":"PHASE3","title":"Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2020-10-27","conditions":"Atopic Dermatitis","enrollment":106},{"nctId":"NCT03131648","phase":"PHASE3","title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-05-30","conditions":"Atopic Dermatitis","enrollment":802},{"nctId":"NCT03761537","phase":"PHASE3","title":"Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-12-13","conditions":"Atopic Dermatitis","enrollment":277},{"nctId":"NCT05387707","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","status":"TERMINATED","sponsor":"Cara Therapeutics, Inc.","startDate":"2022-08-16","conditions":"Pruritus, Atopic Dermatitis","enrollment":287},{"nctId":"NCT03661138","phase":"PHASE3","title":"A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-27","conditions":"Atopic Dermatitis","enrollment":272},{"nctId":"NCT04250337","phase":"PHASE3","title":"Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-03","conditions":"Atopic Dermatitis","enrollment":228},{"nctId":"NCT03809663","phase":"PHASE2","title":"A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-03-15","conditions":"Atopic Dermatitis","enrollment":251},{"nctId":"NCT00120523","phase":"PHASE3","title":"5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2004-04","conditions":"Atopic Dermatitis","enrollment":2418},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT03948334","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-04","conditions":"Atopic Dermatitis","enrollment":123},{"nctId":"NCT04878770","phase":"NA","title":"NMF-CsA-Dupi Trial","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2021-08-16","conditions":"Dermatitis, Atopic","enrollment":318},{"nctId":"NCT03864627","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"Galapagos NV","startDate":"2019-03-25","conditions":"Atopic Dermatitis","enrollment":33},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT03345914","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-17","conditions":"Dermatitis, Atopic","enrollment":367},{"nctId":"NCT03733301","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-16","conditions":"Atopic Dermatitis","enrollment":329},{"nctId":"NCT03983460","phase":"NA","title":"Dupilumab Impact on Skin Resident Memory T Cells","status":"UNKNOWN","sponsor":"Association pour la Recherche Clinique et Immunologique","startDate":"2020-03-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT03100344","phase":"PHASE2","title":"Dose-ranging Study of Nemolizumab in Atopic Dermatitis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-06-14","conditions":"Atopic Dermatitis","enrollment":226},{"nctId":"NCT02317276","phase":"PHASE4","title":"A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2014-12","conditions":"Dermatitis, Atopic","enrollment":11},{"nctId":"NCT02260986","phase":"PHASE3","title":"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-09","conditions":"Atopic Dermatitis","enrollment":740},{"nctId":"NCT01639040","phase":"PHASE2","title":"Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-07","conditions":"Atopic Dermatitis","enrollment":31},{"nctId":"NCT02340234","phase":"PHASE2","title":"A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05","conditions":"Atopic Dermatitis","enrollment":212},{"nctId":"NCT00121381","phase":"PHASE4","title":"Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"Dermatitis, Atopic","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Topical Corticosteroid (TCS)","genericName":"Topical Corticosteroid (TCS)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topical corticosteroids (TCS) are used to treat conditions such as atopic dermatitis, neurodermatitis, and dermatitis. They are small molecule compounds that work to alleviate symptoms of these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}